OpenAI just acquired Orchestra Bio to combine agentic workflows with its Rosalind life sciences suite. The integration is designed to let AI handle coordination hiccups across complex trials and compress the grueling 10-to-15-year drug development cycle for partners like Novo Nordisk and Moderna.
OpenAI just updated GPT-Rosalind, its specialized model series for enterprise life sciences research, baking in GPT-5.5's agentic coding and tool-calling skills. The new model beats GPT-5.5 on wet lab troubleshooting, medicinal chemistry, and genomics while burning up to 31% fewer tokens, aiming to slash the time scientists spend connecting dry-lab data to wet-lab experiments.
OpenAI just partnered with pharma giant Novo Nordisk to embed its frontier models across the company's entire workflow, from lab drug discovery to global distribution. Novo Nordisk aims to simulate lab experiments and crunch complex biological datasets to slash chronic disease drug timelines, while OpenAI trains staff to build custom tools under human oversight.
